Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06921928 | Study for AZD4360 in Participants With Advanced Solid Tumours | PHASE1 | RECRUITING | 117 | — | — | Apr 29, 2025 | Dec 16, 2027 | May 20, 2026 | 18 | United States, China +3 |
To investigate the safety and tolerability, and to determine the Maximum Tolerated Dose (MTD) and/or a Recommended Phase II Dose (R2PD) of AZD4360 in previously treated participants with advanced solid tumours, through the assessment of Dose Limiting Toxicities, Adverse Events and Severe Adverse Events.
| Arm | Type | Description |
|---|---|---|
| AZD4360 Monotherapy | EXPERIMENTAL | AZD4360 Monotherapy |
| Name | Type | Description |
|---|---|---|
| AZD4360 | DRUG | Antibody-Drug Conjugate targeting Claudin 18.2 (CLDN18.2) |
Inclusion Criteria: 1. Participant must be ≥ 18 at the time of signing the ICF. 2. Eastern cooperative oncology group performance status of 0-1 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing. 3. Minimum life expectancy of 12 weeks in the opinion of the Inve...